Evaluation of Two Glatiramer Acetate in Relapsing-Remitting Multiple Sclerosis

- Multiple Sclerosis
- Completed

Study Title: Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients

Teva Identifier: PM034

ClinicalTrials.gov Identifier: NCT01167426

Study Status: Completed

Trial Condition(s): Multiple Sclerosis

Interventions: Drug: Glatiramer Acetate 20 mg/0.5 mL | Drug: Glatiramer acetate 20 mg/0.5 mL

Study Description

Please refer to ClinicalTrials.gov for a description of the trial

Click for participation criteria and map of study locations

Key Participation Requirements

Gender: Female, Male

Age Range: 18 Years and older

Trial Duration: 07/01/2010 - 12/01/2010

Phase: Phase 3

Study Type

Interventional